Stockscreener 앱 받기
20.55
0.10%
0.02
시간 외 거래:
21.25
0.70
+3.41%
전일 마감가:
$20.53
열려 있는:
$20.43
하루 거래량:
989.63K
Relative Volume:
0.67
시가총액:
$2.52B
수익:
$460.48M
순이익/손실:
$142.80M
주가수익비율:
17.42
EPS:
1.18
순현금흐름:
$221.79M
1주 성능:
+0.93%
1개월 성능:
+2.65%
6개월 성능:
-8.75%
1년 성능:
-2.88%
1일 변동 폭
$20.26
$20.58
1주일 범위
$19.90
$21.29
52주 변동 폭
$19.05
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
명칭
Catalyst Pharmaceuticals Inc
전화
(305) 529-2522
주소
355 ALHAMBRA CIRCLE, CORAL GABLES
CPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
20.55 | 2.51B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
416.81 | 104.76B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.67 | 63.06B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.05 | 60.32B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
843.66 | 51.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
165.76 | 34.49B | 398.11M | -1.03B | -868.57M | -5.7032 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-02-04 | 개시 | Robert W. Baird | Outperform |
| 2024-11-18 | 개시 | Stephens | Overweight |
| 2024-03-14 | 개시 | Citigroup | Buy |
| 2024-03-07 | 개시 | BofA Securities | Buy |
| 2023-12-21 | 개시 | Oppenheimer | Outperform |
| 2022-08-24 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 재개 | Piper Jaffray | Overweight |
| 2016-10-05 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | 재확인 | ROTH Capital | Buy |
| 2014-09-16 | 재확인 | ROTH Capital | Buy |
| 2014-09-15 | 재확인 | H.C. Wainwright | Buy |
| 2013-10-21 | 재확인 | Aegis Capital | Buy |
| 2013-09-24 | 개시 | Maxim Group | Buy |
| 2013-09-06 | 재확인 | Aegis Capital | Buy |
| 2013-04-18 | 개시 | Aegis Capital | Buy |
| 2012-08-27 | 업그레이드 | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | 업그레이드 | Merriman | Sell → Neutral |
| 2009-05-29 | 다운그레이드 | Hapoalim | Neutral → Underperform |
| 2009-05-29 | 다운그레이드 | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | 개시 | Merriman Curhan Ford | Buy |
| 2007-11-28 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | 개시 | Stifel Nicolaus | Buy |
| 2007-01-05 | 개시 | First Albany | Buy |
모두보기
Catalyst Pharmaceuticals Inc 주식(CPRX)의 최신 뉴스
What institutional flow reveals about Catalyst Pharmaceuticals Inc.Quarterly Trade Report & Safe Entry Zone Tips - newser.com
Is Catalyst Pharmaceuticals Inc. stock bottoming out2025 Pullback Review & Real-Time Volume Analysis Alerts - newser.com
Why hedge funds are buying Catalyst Pharmaceuticals Inc. stock2025 Volatility Report & Weekly Watchlist for Consistent Profits - Trung tâm Dự báo KTTV quốc gia
How Catalyst Pharmaceuticals Inc. stock benefits from strong dollarPortfolio Growth Summary & Capital Protection Trade Alerts - Trung tâm Dự báo KTTV quốc gia
How Catalyst Pharmaceuticals Inc. stock performs after earningsJuly 2025 Action & Reliable Entry Point Alerts - Trung tâm Dự báo KTTV quốc gia
Published on: 2025-10-17 22:48:25 - newser.com
First Week of June 2026 Options Trading For Catalyst Pharmaceuticals (CPRX) - Nasdaq
What macro factors could drive Catalyst Pharmaceuticals Inc. (CN2) stock higherWeekly Earnings Recap & High Win Rate Trade Alerts - newser.com
Why Catalyst Pharmaceuticals Inc. stock is favored by pension fundsWeekly Volume Report & Entry and Exit Point Strategies - newser.com
Using flow based indicators on Catalyst Pharmaceuticals Inc.July 2025 Market Mood & Advanced Technical Analysis Signals - newser.com
How to use Fibonacci retracement on Catalyst Pharmaceuticals Inc.Market Risk Summary & Daily Market Momentum Tracking - newser.com
Catalyst Pharmaceuticals Shares Climb as New Drug Developments Spark Fresh Valuation Debate - Yahoo Finance
Can Catalyst Pharmaceuticals Inc. (CN2) stock surprise with quarterly resultsBuy Signal & Weekly Breakout Opportunity Watchlist - newser.com
Catalyst Pharmaceuticals (CPRX): Assessing Valuation on Clinical Progress and Expanding Rare Disease Pipeline - Sahm
Assessing Catalyst Pharmaceuticals’ Value After Recent Positive FDA Ruling in 2025 - Sahm
Catalyst Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Should Catalyst Pharmaceuticals’ (CPRX) Share Buyback and New Data Prompt a Fresh Look at Its Strategy? - Sahm
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term - sharewise.com
Using Ichimoku Cloud for Catalyst Pharmaceuticals Inc. technicalsWatch List & Consistent Growth Equity Picks - newser.com
Published on: 2025-10-10 04:19:27 - newser.com
Will earnings trigger a reversal in Catalyst Pharmaceuticals Inc.Portfolio Return Summary & Fast Gaining Stock Strategy Reports - newser.com
Catalyst Pharmaceuticals (NASDAQ:CPRX) Earns "Hold (C+)" Rating from Weiss Ratings - MarketBeat
Catalyst Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences - GlobeNewswire
Catalyst Pharmaceuticals to Present Research on Duchenne Muscular Dystrophy and Lambert Eaton Myasthenic Syndrome at Upcoming Scientific Conferences - Quiver Quantitative
3 Presentations: Catalyst Pharmaceuticals to present DMD & LEMS data at Oct 2025 conferences - Stock Titan
Real time breakdown of Catalyst Pharmaceuticals Inc. stock performance2025 Trading Volume Trends & Weekly High Potential Alerts - newser.com
Catalyst Pharmaceuticals Delivers Growth But Faces Narrow Pipeline Risk - Finimize
Published on: 2025-10-09 00:54:28 - newser.com
Lambert Eaton Myasthenic Syndrome Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Jacobus Pharmaceutical, Catalyst Pharmaceuticals - Barchart.com
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term - Yahoo Finance
What do Analysts Think About Catalyst Pharmaceuticals (CPRX)? - Insider Monkey
Catalyst Pharmaceuticals, Inc. (CPRX) Stock Analysis: Significant Upside Potential with 65% Growth Projection - DirectorsTalk Interviews
14 Biotech Stocks with High Potential - Insider Monkey
Will Catalyst Pharmaceuticals Inc. rebound enough to break evenTrade Risk Assessment & Daily Technical Forecast Reports - newser.com
Published on: 2025-10-06 05:08:49 - newser.com
Assessing Catalyst Pharmaceuticals (CPRX) Valuation After $200 Million Share Buyback Announcement - Yahoo Finance
Detecting price anomalies in Catalyst Pharmaceuticals Inc. with AIEarnings Summary Report & Long-Term Capital Growth Ideas - newser.com
A Closer Look at Catalyst Pharmaceuticals (CPRX) Valuation as Shares Remain Steady This Week - Sahm
Order flow analysis tools used on Catalyst Pharmaceuticals Inc.Weekly Trade Review & Capital Efficiency Focused Strategies - newser.com
Wealth Enhancement Advisory Services LLC Lowers Stock Position in Catalyst Pharmaceuticals, Inc. $CPRX - Defense World
Wall Street Zen Downgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) to Hold - MarketBeat
Why Catalyst Pharmaceuticals Inc. (CN2) stock could break out in 2025July 2025 Weekly Recap & Stepwise Entry/Exit Trade Alerts - newser.com
Catalyst Pharmaceuticals Inc. stock daily chart insightsJuly 2025 Selloffs & Fast Momentum Stock Entry Tips - newser.com
Catalyst Pharmaceuticals Inc (CPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.84%
0.50%
자본화:
|
볼륨(24시간):